Jasper Therapeutics, Inc. (JSPR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer,
How this was made
The 30-second read
Why it matters
The departure may cause short‑term volatility, but the company's ongoing operations and pipeline remain unchanged.
Market read
Executive turnover is a material corporate event for a micro‑cap biotech, likely prompting modest price movement.
What to watch
Potential cost savings from restructuring the finance team or undisclosed strategic shifts.
Background
The filing is a standard SEC 8‑K disclosure of officer changes, providing the first public notice of the CFO's exit and interim replacements.
Ticker impact
Jasper Therapeutics filed an 8‑K announcing the CFO's resignation and interim appointments of senior officers.
likely modest downside pressure as investors price in the CFO departure.
Executive turnover, especially at the CFO level, often triggers short‑term sell pressure absent a clear succession plan.
Market effects
Minimal impact on the broader biotech sector; similar firms may see slight attention to governance.
U.S. market only; no regional ripple.
Limited to investors tracking small‑cap biotech equities.
Counterpoint
The interim appointments could be seen as a smooth transition, limiting any negative price impact.
Key entities
- personHerb Cross
Outgoing CFO, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary.
- personJeet Mahal
CEO appointed as interim Principal Financial Officer.
- personRick Ruiz
Vice President, Finance appointed as interim Principal Accounting Officer.
- personMatthew Ros
COO appointed as interim Corporate Secretary.
